Denosumab

• CAT Number: I043755
• CAS Number: 615258-40-7
• Molecular Formula: C6404H9908N1724O2004S50
• Molecular Weight: 144716.86
• Purity: ≥95%

Denosumab (Cat No.: I043755) is a fully human monoclonal antibody that targets RANKL (receptor activator of nuclear factor-kappa B ligand), a key mediator of bone resorption. By inhibiting RANKL, denosumab prevents the formation, function, and survival of osteoclasts, thereby reducing bone loss. It is used to treat conditions like osteoporosis, bone metastases, and giant cell tumor of bone. Administered via subcutaneous injection, denosumab improves bone density and reduces fracture risk, offering an effective alternative to bisphosphonates in managing bone-related disorders.

Reference

[1]. Moen MD, et al. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging. 2011;28(1):63-82.
[Content Brief]

[2]. Chawla S, et al. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019;20(12):1719-1729.
[Content Brief]